Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury – and getting them to stay there – remains challenging. In a new pilot study using an animal model, North Carolina State University researcher Ke Cheng and his team show that “decorating” cardiac stem cells with platelet nanovesicles can increase the stem cells’ ability to find and remain at the site of heart attack injury and enhance their effectiveness in treatment.
“Platelets can home in on an injury site and stay there, and even in some cases recruit a body’s own naturally occurring stem cells to the site, but they are a double-edged sword,” says Cheng, associate professor of veterinary medicine and associate professor in the NC State/UNC Joint Department of Biomedical Engineering. “That’s because once the platelets arrive at the site of injury, they trigger the coagulation processes that cause clotting. In a heart-attack injury, blood clots are the last thing that you want.”
Cheng and his associates wondered if it would be possible to co-opt a platelet’s ability to locate and stick to an injury site without inducing clotting. They found that adhesion molecules (a group of glycoproteins) located on the platelet’s surface were responsible for its ability to find and bind to an injury. So the team created platelet nanovesicles from these molecules, and then decorated the surface of cardiac stem cells with the nanovesicles.
“The nanovesicle is like the platelet’s coat,” Cheng says. “There isn’t any internal cellular machinery that could activate clotting. When you place the nanovesicle on the stem cell, it’s like giving the stem cell a tiny GPS that helps it locate the injury so it can do its repair work without any of the side effects associated with live platelets.”
In a proof-of-concept study involving a rat model of myocardial infarction, twice as many platelet nanovesicle decorated cardiac stem cells, or PNV-CSCs, were retained in the heart than non-decorated cardiac stem cells. The rodents were monitored for four weeks. Overall, the rats in the PNV-CSC group showed nearly 20 percent or higher cardiac function than the control CSC group.
A small pilot study in a pig model also demonstrated higher rates of stem cell retention with PNV-CSCs, though the team did not perform functional studies. A future follow-up study is planned.
“Platelet nanovesicles do not affect the performance of the cardiac stem cells, and are free from any negative side effects,” Cheng says. “Hopefully we will be able to use this approach to improve cardiac stem cell therapy in clinical trials in the future.”
Stem cell transplantation, as used clinically, suffers from low retention and engraftment of the transplanted cells. Inspired by the ability of platelets to recruit stem cells to sites of injury on blood vessels, we hypothesized that platelets might enhance the vascular delivery of cardiac stem cells (CSCs) to sites of myocardial infarction injury. Here, we show that CSCs with platelet nanovesicles fused onto their surface membranes express platelet surface markers that are associated with platelet adhesion to injury sites. We also find that the modified CSCs selectively bind collagen-coated surfaces and endothelium-denuded rat aortas, and that in rat and porcine models of acute myocardial infarction the modified CSCs increase retention in the heart and reduce infarct size. Platelet-nanovesicle-fused CSCs thus possess the natural targeting and repairing ability of their parental cell types. This stem cell manipulation approach is fast, straightforward and safe, does not require genetic alteration of the cells, and should be generalizable to multiple cell types.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.